Donald Poretz, MD
Infectious Disease · Annandale, VANPI 1164478095
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.8%), gifts and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 35.3% of the total. Reporting peaked in 2019 at $1,515 and has fallen 98.2% since, to $27 in 2024.
Across 131 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$645
- Viiv Healthcare Company$350
- Merck$272
- Gilead$222
- Johnson & Johnson$199
- plus $559 from 10 others
Across 257 payments — averaging $6871.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.2M
- Bavarian Nordic A/s$385K
- AbbVie$164K
What the payments were for
- Consulting fees$60017%
- Speaking & faculty fees$211%
- Food & beverage$1,86854%
- Gifts$98128%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $1,224 |
| Pfizer | 4 | $645 |
| Viiv Healthcare Company | 19 | $350 |
| Merck | 17 | $272 |
| Gilead | 15 | $222 |
| Johnson & Johnson | 12 | $199 |
| Melinta Therapeutics, LLC | 5 | $107 |
| Philips North America LLC | 4 | $81 |
| Paratek Pharmaceuticals, Inc. | 3 | $68 |
| Insmed, Inc. | 4 | $65 |
| Mylan Institutional Inc. | 3 | $63 |
| Napo Pharmaceuticals Inc | 3 | $56 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 2 | $40 |
| Dynavax Technologies Corporation | 1 | $15 |
| Qiagen, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX COSMETIC$961
How this compares
$3,471 in reported general payments places this provider in the 80th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 98 | $445,769 |
| JulucaDolutegravir/Rilpivirine | 34 | $117,042 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 25 | $104,492 |
| DovatoDolutegravir Sodium/Lamivudine | 14 | $66,735 |
| Fosfomycin Tromethamine | 21 | $3,228 |
| CefuroximeCefuroxime Axetil | 41 | $2,909 |
| Rifabutin | 14 | $2,814 |
| Testosterone | 14 | $2,797 |
| Vancomycin Hcl | 18 | $2,284 |
| ValacyclovirValacyclovir Hcl | 16 | $924 |
| Rifampin | 16 | $685 |
| Clindamycin Hcl | 22 | $535 |
| Azithromycin | 25 | $534 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 35 | $507 |
| Linezolid | 13 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $222 | $550,262123 claims |
| Viiv Healthcare CompanyJuluca, Dovato | $350 | $183,77748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Annandale
- David WheelerAnnandale$49K
- Allan MorrisonAnnandale$4K
- Jennifer MakhoulAnnandale$1K
- Sujata AmbardarAnnandale$891
- Mark DelmanAnnandale$739
- Christopher BettacchiMarion$243K
- Stephen WeinrothFairfax$157K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
- Valerie RiddleBumpass$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.